On the stock market since 1997, it operates in the world of health and science. It has 3 employees. Now — the numbers.
This is an established company with proven profits.
An average decline of 16% a year over the last 4 years — the most striking risk in this picture. Red columns mark years that ended in a loss.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
Debt is low and cash is strong; the finances stand solid.
The price looks reasonable next to what the company earns.
There is growth, but not at top-of-the-class tempo.
The price is looking for direction — no strong breakout, no collapse.
No real weak spot in any of the five subjects — a balanced report card.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Bets Against the Stock: The number of investors betting on a fall stands out.
The stock trades 32% below its peak. The market has trimmed its expectations for the company.
The net profit margin is 30% — still a thick cushion, though costs have been eating into it lately.
It pays out $645 per share each year — regular cash for whoever holds the stock.
Over the last 3 years, sales fell about 21% a year on average. Profit is holding up, but a shrinking business is a risk worth watching.
The weight of investors positioned for a fall can be felt in the market. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 2/10.
On our five-subject report card, FPCG sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: FPCG is an established business that has proven its profits for years. The real debate here isn’t the price — it’s whether the company can keep up this pace.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.